| Nov 20 |
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
|
| Oct 17 |
Exscientia advances two additional discovery programs with Sanofi
|
| Oct 16 |
Exscientia to receive $15M in milestones for Sanofi collaboration
|
| Oct 16 |
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
|
| Oct 12 |
Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery
|
| Oct 11 |
Exscientia Set for Strategic Acquisition by Recursion
|
| Oct 10 |
Recursion, Exscientia seek support for merger ahead of special meeting
|
| Oct 9 |
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
|
| Oct 4 |
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
|
| Oct 2 |
Exscientia outline robot and AI use in drug discovery workflow
|
